Zydus Lifesciences Limited (ZYDUSLIFE) — Financial Results | 6 February 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Zydus Lifesciences reported consolidated revenue of ₹87.22 crores for Q3 FY2025, reflecting a 32% YoY growth driven by strong domestic and international performance. The company highlighted robust demand across key therapeutic segments and improved operational efficiency. Management emphasized sustained momentum in specialty formulations and expansion in emerging markets during the quarter.

📄 View Original Announcement (PDF)

About Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,01,800.69 Cr P/E: 22.5

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ZYDUSLIFE — Free

Free account · 2 AI queries/day